(1)                Traitement des cancers bronchiques non à petites cellules et résécables. Recommandations de pratique clinique de l'European Lung Cancer working Party. Rev Med Brux 2006;27:29-38.

       (2)                European Lung Cancer Working Party. Traitement des cancers bronchiques non à petites cellules, non métastatiques et non résécables : les recommandations de pratique clinique de l'European Lung Cancer Working Party. Rev Med Brux 2006 May;27(3):152-61.

       (3)                European Lung Cancer Working Party (E.L.C.W.P.). Les recommandations de pratique clinique de l'European Lung Cancer Working Party. Cancers bronchiques non à petites cellules: III. Maladies avancées (métastatiques). Rev Med Brux 2007;28(6):495-511.

       (4)                Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care 2003 Feb;12(1):18-23.

       (5)    Burgers JS, Fervers B, Haugh M, Brouwers M, Browman G, Philip T, et al. International assessment of the quality of clinical practice guidelines in oncology using the Appraisal of Guidelines and Research and Evaluation Instrument. J Clin Oncol 2004 May 15;22(10):2000-7.

       (6)    Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1997 Aug;15(8):2996-3018.

       (7)    Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004 Jan 15;22(2):330-53.

       (8)    BTS guidelines: guidelines on the selection of patients with lung cancer for surgery. Thorax 2001 Feb;56(2):89-108.

       (9)    Levine M, Browman G, Newman T, Cowan DH. The Ontario Cancer Treatment Practice Guidelines Initiative. Oncology (Huntingt) 1996 Nov;10(11 Suppl):19-22.

     (10)    Laurie SA, Logan D, Markman BR, Mackay JA, Evans WK. Practice guideline for the role of combination chemotherapy in the initial management of limited-stage small-cell lung cancer. Lung Cancer 2004 Feb;43(2):223-40.

     (11)    The Royal College of Radiologists Clinical Oncology Information Network. Guidelines on the non-surgical management of lung cancer. Clin Oncol (R Coll Radiol ) 1999;11(1):S1-S53.

     (12)    Alberts WM. Lung Cancer Guidelines. Introduction. Chest 2003;123:1S-2S.

     (13)    Simon GR, Turrisi A. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007 Sep;132(3 Suppl):324S-39S.

     (14)    Depierre A, Lagrange JL, Theobald S, Astoul P, Baldeyrou P, Bardet E, et al. Standards, Options and Recommendations for the management of non-small cell lung carcinoma patients. Br J Cancer 2003 Aug;89 Suppl 1:S35-S49.

     (15)    McCrory DC, Colice GL, Lewis SZ, Alberts WM, Parker S. Overview of methodology for lung cancer evidence review and guideline development. Chest 2003 Jan;123(1 Suppl):3S-6S.

     (16)    Cancer du poumon à petites cellules. Chimiothérapie + radiothérapie mais beaucoup de rechutes. Rev Prescrire 2007;27(282):289-91.

     (17)                Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997 Jun;111(6):1710-7.

     (18)    Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3 1973 Mar;4(2):31-42.

     (19)    Stahel R, Aisner J, Ginsberg R, Havemann K, Hirsch F, Ihde DC. Staging and prognostic factors in small cell lung carcinoma. Consensus report. In: Hansen HH, Kristjansen PE, editors. Management of small cell lung cancer.Amsterdam: Elsevier; 1989. p. 1-8.

     (20)    Simon GR, Wagner H. Small cell lung cancer. Chest 2003 Jan;123(1 Suppl):259S-71S.

     (21)                Kosmidis PA, Samantas E, Fountzilas G, Pavlidis N, Apostolopoulou F, Skarlos D. Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Hellenic Cooperative Oncology Group for Lung Cancer Trials. Semin Oncol 1994 Jun;21(3 Suppl 6):23-30.

     (22)    Lassen U, Kristjansen PE, Osterlind K, Bergman B, Sigsgaard TC, Hirsch FR, et al. Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer. A randomized trial with 5 years follow up. Ann Oncol 1996 Apr;7(4):365-71.

     (23)                Tummarello D, Graziano F, Mari D, Cetto G, Pasini F, Antonio S, et al. Small cell lung cancer (SCLC): a randomized trial of cyclophosphamide, adriamycin, vincristine plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, followed in complete responders by alpha- interferon or no treatment, as maintenance therapy. Anticancer Res 1994 Sep;14(5B):2221-7.

     (24)    Sculier JP, Bureau G, Giner V, Thiriaux J, Michel J, Berchier MC, et al. Induction chemotherapy with ifosfamide, etoposide, and anthracycline for small cell lung cancer: experience of the European Lung Cancer Working Party. Semin Oncol 1995 Feb;22(1 Suppl 2):18-22.

     (25)                Mavroudis D, Papadakis E, Veslemes M, Tsiafaki X, Stavrakakis J, Kouroussis C, et al. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Ann Oncol 2001 Apr;12(4):463-70.

     (26)    Reck M, von Pawel J, Macha HN, Kaukel E, Deppermann KM, Bonnet R, et al. Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer. J Natl Cancer Inst 2003 Aug 6;95(15):1118-27.

     (27)    Niell HB, Herndon JE, Miller AA, Watson DM, Sandler AB, Kelly K, et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol 2005 Jun 1;23(16):3752-9.

     (28)    Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002 Jan 10;346(2):85-91.

     (29)    Hanna N, Bunn PA, Jr., Langer C, Einhorn L, Guthrie T, Jr., Beck T, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006 May 1;24(13):2038-43.

     (30)    Eckardt JR, von PJ, Papai Z, Tomova A, Tzekova V, Crofts TE, et al. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J Clin Oncol 2006 May 1;24(13):2044-51.

     (31)    Mascaux C, Paesmans M, Berghmans T, Branle F, Lafitte JJ, Lemaitre F, et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 2000 Oct;30(1):23-36.

     (32)    Pujol JL, Carestia L, Daures JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 2000 Jul;83(1):8-15.

     (33)    Sculier JP, Berghmans T, Castaigne C, Luce S, Sotiriou C, Vermylen P, et al. Maintenance chemotherapy for small cell lung cancer: a critical review of the literature. Lung Cancer 1998 Feb;19(2):141-51.

     (34)    Bozcuk H, Artac M, Ozdogan M, Savas B. Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? A metaanalysis of the published controlled trials. Cancer 2005 Dec 15;104(12):2650-7.

     (35)    Schiller JH, Adak S, Cella D, DeVore RF, III, Johnson DH. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2001 Apr 15;19(8):2114-22.

     (36)    Hanna NH, Sandier AB, Loehrer PJ, Sr., Ansari R, Jung SH, Lane K, et al. Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study. Ann Oncol 2002 Jan;13(1):95-102.

     (37)    Pujol JL, Douillard JY, Riviere A, Quoix E, Lagrange JL, Berthaud P, et al. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study. J Clin Oncol 1997 May;15(5):2082-9.

     (38)                Berghmans T, Paesmans M, Lafitte JJ, Mascaux C, Meert AP, Sculier JP. Role of granulocyte and granulocyte-macrophage colony-stimulating factors in the treatment of small-cell lung cancer: a systematic review of the literature with methodological assessment and meta-analysis. Lung Cancer 2002 Aug;37(2):115-23.

     (39)    Humblet Y, Symann M, Bosly A, Delaunois L, Francis C, Machiels J, et al. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. J Clin Oncol 1987 Dec;5(12):1864-73.

     (40)    Lorigan P, Woll PJ, O'Brien ME, Ashcroft LF, Sampson MR, Thatcher N. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer. J Natl Cancer Inst 2005 May 4;97(9):666-74.

     (41)                Havemann K, Wolf M, Holle R, Gropp C, Drings P, Manke HG, et al. Alternating versus sequential chemotherapy in small cell lung cancer. A randomized German multicenter trial. Cancer 1987 Mar 15;59(6):1072-82.

     (42)    Evans WK, Feld R, Murray N, Willan A, Coy P, Osoba D, et al. Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada [published erratum appears in Ann Intern Med 1988 Mar;108(3):496]. Ann Intern Med 1987 Oct;107(4):451-8.

     (43)    Ettinger DS, Finkelstein DM, Abeloff MD, Ruckdeschel JC, Aisner SC, Eggleston JC. A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group. J Clin Oncol 1990 Feb;8(2):230-40.

     (44)    Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991 Jun 19;83(12):855-61.

     (45)    Urban T, Chastang C, Lebas FX, Duhamel JP, Adam G, Darse J, et al. The addition of cisplatin to cyclophosphamide-doxorubicin-etoposide combination chemotherapy in the treatment of patients with small cell lung carcinoma: A randomized study of 457 patients. "Petites Cellules" Group. Cancer 1999 Dec 1;86(11):2238-45.

     (46)    Lebeau B, Chastang C, Brechot JM, Capron F, Dautzenberg B, Delaisements C, et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer 1994 Jul 1;74(1):38-45.

     (47)                Shepherd FA, Giaccone G, Seymour L, Debruyne C, Bezjak A, Hirsh V, et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002 Nov 15;20(22):4434-9.

     (48)    Cheng S, Evans WK, Stys-Norman D, Shepherd FA. Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol 2007 Apr;2(4):348-54.

     (49)    O'Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cucevia B, Juhasz G, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006 Dec 1;24(34):5441-7.

     (50)    von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999 Feb;17(2):658-67.

     (51)    von Pawel J, Gatzemeier U, Pujol JL, Moreau L, Bildat S, Ranson M, et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 2001 Mar 15;19(6):1743-9.

     (52)    Sculier JP, Lafitte JJ, Lecomte J, Berghmans T, Thiriaux J, Van Cutsem O, et al. A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer. Ann Oncol 2002 Sep;13(9):1454-9.

     (53)    Maurer LH, Tulloh M, Weiss RB, Blom J, Leone L, Glidewell O, et al. A randomized combined modality trial in small cell carcinoma of the lung: comparison of combination chemotherapy-radiation therapy versus cyclophosphamide-radiation therapy effects of maintenance chemotherapy and prophylactiv whole brain irradiation. Cancer 1980 Jan 1;45(1):30-9.

     (54)    Cullen M, Morgan D, Gregory W, Robinson M, Cox D, McGivern D, et al. Maintenance chemotherapy for anaplastic small cell carcinoma of the bronchus: a randomised, controlled trial. Cancer Chemother Pharmacol 1986;17(2):157-60.

     (55)    Einhorn LH, Crawford J, Birch R, Omura G, Johnson DH, Greco FA. Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer. J Clin Oncol 1988 Mar;6(3):451-6.

     (56)                Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Report to the Medical Research Council by its Lung Cancer Working Party. Br J Cancer 1989 Apr;59(4):584-90.

     (57)    Spiro SG, Souhami RL, Geddes DM, Ash CM, Quinn H, Harper PG, et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer 1989 Apr;59(4):578-83.

     (58)    Byrne MJ, van Hazel G, Trotter J, Cameron F, Shepherd J, Cassidy B, et al. Maintenance chemotherapy in limited small cell lung cancer: a randomised controlled clinical trial. Br J Cancer 1989 Sep;60(3):413-8.

     (59)    Mattson K, Niiranen A, Pyrhonen S, Holsti LR, Holsti P, Kumpulainen E, et al. Natural interferon alfa as maintenance therapy for small cell lung cancer. Eur J Cancer 1992;28A(8-9):1387-91.

     (60)    Lebeau B, Chastang C, Allard P, Migueres J, Boita F, Fichet D. Six vs twelve cycles for complete responders to chemotherapy in small cell lung cancer: definitive results of a randomized clinical trial. The "Petites Cellules" Group. Eur Respir J 1992 Mar;5(3):286-90.

     (61)                Giaccone G, Dalesio O, McVie GJ, Kirkpatrick A, Postmus PE, Burghouts JT, et al. Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1993 Jul;11(7):1230-40.

     (62)    Bleehen NM, Girling DJ, Machin D, Stephens RJ. A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). I: Survival and prognostic factors. Medical Research Council Lung Cancer Working Party. Br J Cancer 1993 Dec;68(6):1150-6.

     (63)    Sculier JP, Paesmans M, Bureau G, Giner V, Lecomte J, Michel J, et al. Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party. J Clin Oncol 1996 Aug;14(8):2337-44.

     (64)    Beith JM, Clarke SJ, Woods RL, Bell DR, Levi JA. Long-term follow-up of a randomised trial of combined chemoradiotherapy induction treatment, with and without maintenance chemotherapy in patients with small cell carcinoma of the lung. Eur J Cancer 1996 Mar;32A(3):438-43.

     (65)                Edmonson JH, Lagakos SW, Selawry OS, Perlia CP, Bennett JM, Muggia FM, et al. Cyclophosphamide and CCNU in the treatment of inoperable small cell carcinoma and adenocarcinoma of the lung. Cancer Treat Rep 1976 Jul;60(7):925-32.

     (66)    Hansen HH, Dombernowsky P, Hansen M, Hirsch F. Chemotherapy of advanced small-cell anaplastic carcinoma. Superiority of a four-drug combination to a three-drug combination. Ann Intern Med 1978 Aug;89(2):177-81.

     (67)    Ettinger DS, Lagakos S. Phase III study of CCNU, cyclophosphamide, adriamycin, vincristine, and VP-16 in small-cell carcinoma of the lung. Cancer 1982 Apr 15;49(8):1544-54.

     (68)    Jackson DVJ, Zekan PJ, Caldwell RD, Slatkoff ML, Harding RW, Case LD, et al. VP-16-213 in combination chemotherapy with chest irradiation for small- cell lung cancer: a randomized trial of the Piedmont Oncology Association. J Clin Oncol 1984 Dec;2(12):1343-51.

     (69)                Lowenbraun S, Birch R, Buchanan R, Krauss S, Durant J, Perez C, et al. Combination chemotherapy in small cell lung carcinoma. A randomized study of two intensive regimens. Cancer 1984 Dec 1;54(11):2344-50.

     (70)    Zhiyi Z, Shenzhong W, Xiafang Z. Small cell carcinoma of the lung ; results of a combination chemotherapy and radiation therapy (COF vs COFP randomized analyzed). Int J Radiat Oncol Biol Phys 1984;10:2139-43.

     (71)    Messeih AA, Schweitzer JM, Lipton A, Harvey HA, Simmonds MA, Stryker JA, et al. Addition of etoposide to cyclophosphamide, doxorubicin, and vincristine for remission induction and survival in patients with small cell lung cancer. Cancer Treat Rep 1987 Jan;71(1):61-6.

     (72)    Jackson DVJ, Case LD, Zekan PJ, Powell BL, Caldwell RD, Bearden JD, et al. Improvement of long-term survival in extensive small-cell lung cancer. J Clin Oncol 1988 Jul;6(7):1161-9.

     (73)    Niiranen A, Holsti P, Salmo M. Treatment of small cell lung cancer. Two-drug versus four-drug chemotherapy and loco-regional irradiation with or without prophylactic cranial irradiation. Acta Oncol 1989;28(4):501-5.

     (74)    Jett JR, Everson L, Therneau TM, Krook JE, Dalton RJ, Marschke RFJ, et al. Treatment of limited-stage small-cell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without etoposide: a randomized trial of the North Central Cancer Treatment Group. J Clin Oncol 1990 Jan;8(1):33-8.

     (75)    Sculier JP, Klastersky J, Libert P, Ravez P, Thiriaux J, Lecomte J, et al. A randomized study comparing etoposide and vindesine with or without cisplatin as induction therapy for small cell lung cancer. EORTC Lung Cancer Working Party. Ann Oncol 1990;1(2):128-33.

     (76)                Nikkanen V, Liippo K, Ojala A, Jakobsson M, Jarvinen M, Paloheimo S, et al. Vincristine, doxorubicin and cyclophosphamide with and without etoposide in limited small cell lung cancer. Acta Oncol 1990;29(4):421-4.

     (77)    Smith AP, Anderson G, Chappell G, Bowen DR. Does the substitution of cisplatin in a standard four drug regimen improve survival in small cell carcinoma of the lung? A comparison of two chemotherapy regimens. Thorax 1991 Mar;46(3):172-4.

     (78)                Miyamoto H, Nakabayashi T, Isobe H, Akita H, Kawakami Y, Arimoto T, et al. A phase III comparison of etoposide/cisplatin with or without added ifosfamide in small-cell lung cancer. Oncology 1992;49(6):431-5.

     (79)                Gatzemeier U, Pawel JV, Laumen R, Hossfeld DK, Neuhauss R. Etoposide/vincristine-based chemotherapy with or without carboplatin in extensive-stage small cell lung cancer: a prospective randomized phase III trial. Semin Oncol 1994 Jun;21(3 Suppl 6):31-5.

     (80)    Loehrer PJS, Ansari R, Gonin R, Monaco F, Fisher W, Sandler A, et al. Cisplatin plus etoposide with and without ifosfamide in extensive small- cell lung cancer: a Hoosier Oncology Group study. J Clin Oncol 1995 Oct;13(10):2594-9.

     (81)                Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. Medical Research Council Lung Cancer Working Party [published erratum appears in Br J Cancer 1996 Sep;74(6):997]. Br J Cancer 1996 Feb;73(3):406-13.

     (82)    Hirsch FR, Osterlind K, Jeppesen N, Dombernowsky P, Ingeberg S, Sorensen PG, et al. Superiority of high-dose platinum (cisplatin and carboplatin) compared to carboplatin alone in combination chemotherapy for small-cell lung carcinoma: a prospective randomised trial of 280 consecutive patients. Ann Oncol 2001 May;12(5):647-53.

     (83)    Pujol JL, Daures JP, Riviere A, Quoix E, Westeel V, Quantin X, et al. Etoposide Plus Cisplatin With or Without the Combination of 4'-Epidoxorubicin Plus Cyclophosphamide in Treatment of Extensive Small-Cell Lung Cancer: a French Federation of Cancer Institutes Multicenter Phase III Randomized Study. J Natl Cancer Inst 2001 Feb 21;93(4):300-8.

     (84)    De Marinis F, Nelli F, Lombardo M, Ferrau F, Barbera S, Bertetto O, et al. A multicenter, randomized, Phase II study of cisplatin, etoposide, and gemcitabine or cisplatin plus gemcitabine as first-line treatment in patients with poor-prognosis small cell lung carcinoma. Cancer 2005 Feb 15;103(4):772-9.

     (85)    Cohen MH, Creaven PJ, Fossieck BEJ, Broder LE, Selawry OS, Johnston AV, et al. Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep 1977 May;61(3):349-54.

     (86)                Figueredo AT, Hryniuk WM, Strautmanis I, Frank G, Rendell S. Co-trimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer. J Clin Oncol 1985 Jan;3(1):54-64.

     (87)                O'Donnell MR, Ruckdeschel JC, Baxter D, McKneally MF, Caradonna R, Horton J. Intensive induction chemotherapy for small cell anaplastic carcinoma of the lung. Cancer Treat Rep 1985 Jun;69(6):571-5.

     (88)    Wolff SN, Birch R, Sarma P, Greco FA. Randomized dose-response evaluation of etoposide in small cell carcinoma of the lung: a Southeastern Cancer Study Group Trial. Cancer Treat Rep 1986 May;70(5):583-7.

     (89)    Johnson DH, Einhorn LH, Birch R, Vollmer R, Perez C, Krauss S, et al. A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1987 Nov;5(11):1731-8.

     (90)                Arriagada R, Le Chevalier T, Pignon JP, Riviere A, Monnet I, Chomy P, et al. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 1993 Dec 16;329(25):1848-52.

     (91)    Ihde DC, Mulshine JL, Kramer BS, Steinberg SM, Linnoila RI, Gazdar AF, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 1994 Oct;12(10):2022-34.

     (92)    Sculier JP, Paesmans M, Bureau G, Dabouis G, Libert P, Vandermoten G, et al. Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party. J Clin Oncol 1993 Oct;11(10):1858-65.

     (93)    Souhami RL, Rudd R, Ruiz dEM, James L, Gower N, Harper PG, et al. Randomized trial comparing weekly versus 3-week chemotherapy in small- cell lung cancer: a Cancer Research Campaign trial. J Clin Oncol 1994 Sep;12(9):1806-13.

     (94)    James LE, Gower NH, Rudd RM, Spiro SG, Harper PG, Trask CW, et al. A randomised trial of low-dose/high-frequency chemotherapy as palliative treatment of poor-prognosis small-cell lung cancer: a Cancer research Campaign trial. Br J Cancer 1996 Jun;73(12):1563-8.

     (95)    Furuse K, Fukuoka M, Nishiwaki Y, Kurita Y, Watanabe K, Noda K, et al. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group. J Clin Oncol 1998 Jun;16(6):2126-32.

     (96)    Murray N, Livingston RB, Shepherd FA, James K, Zee B, Langleben A, et al. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 1999 Aug;17(8):2300-8.

     (97)    Sekine I, Nishiwaki Y, Noda K, Kudoh S, Fukuoka M, Mori K, et al. Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI). Ann Oncol 2003 May;14(5):709-14.

     (98)                Ardizzoni A, Tjan-Heijnen VC, Postmus PE, Buchholz E, Biesma B, Karnicka-Mlodkowska H, et al. Standard Versus Intensified Chemotherapy With Granulocyte Colony-Stimulating Factor Support in Small-Cell Lung Cancer: A Prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923. J Clin Oncol 2002 Oct 1;20(19):3947-55.

     (99)                Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991 Jul 18;325(3):164-70.

   (100)    Trillet-Lenoir V, Green J, Manegold C, von Pawel J, Gatzemeier U, Lebeau B, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29A(3):319-24.

   (101)    Trillet-Lenoir V, Green JA, Manegold C, von Pawel J, Gatzemeier U, Lebeau B, et al. Recombinant granulocyte colony stimulating factor in the treatment of small cell lung cancer: a long-term follow-up [letter]. Eur J Cancer 1995 Nov;31A(12):2115-6.

   (102)    Hamm J, Schiller JH, Cuffie C, Oken M, Fisher RI, Shepherd F, et al. Dose-ranging study of recombinant human granulocyte-macrophage colony- stimulating factor in small-cell lung carcinoma. J Clin Oncol 1994 Dec;12(12):2667-76.

   (103)    Bunn PAJ, Crowley J, Kelly K, Hazuka MB, Beasley K, Upchurch C, et al. Chemoradiotherapy with or without granulocyte-macrophage colony- stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group [published erratum appears in J Clin Oncol 1995 Nov;13(11):2860]. J Clin Oncol 1995 Jul;13(7):1632-41.

   (104)    Steward WP, von Pawel J, Gatzemeier U, Woll P, Thatcher N, Koschel G, et al. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients. J Clin Oncol 1998 Feb;16(2):642-50.

   (105)    Fukuoka M, Masuda N, Negoro S, Matsui K, Yana T, Kudoh S, et al. CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. Br J Cancer 1997;75(2):306-9.

   (106)                Gatzemeier U, Kleisbauer JP, Drings P, Kaukel E, Samaras N, Melo MJ, et al. Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a phase III, multicenter, randomized study. Am J Clin Oncol 2000 Aug;23(4):393-400.

   (107)    Miles DW, Fogarty O, Ash CM, Rudd RM, Trask CW, Spiro SG, et al. Received dose-intensity: a randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. J Clin Oncol 1994 Jan;12(1):77-82.

   (108)    Woll PJ, Hodgetts J, Lomax L, Bildet F, Cour-Chabernaud V, Thatcher N. Can cytotoxic dose-intensity be increased by using granulocyte colony- stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol 1995 Mar;13(3):652-9.

   (109)    Thatcher N, Girling DJ, Hopwood P, Sambrook RJ, Qian W, Stephens RJ. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party. J Clin Oncol 2000 Jan;18(2):395-404.

   (110)    Woll PJ, Thatcher N, Lomax L, Hodgetts J, Lee SM, Burt PA, et al. Use of hematopoietic progenitors in whole blood to support dose-dense chemotherapy: a randomized phase II trial in small-cell lung cancer patients. J Clin Oncol 2001 Feb 1;19(3):712-9.

   (111)    Sculier JP, Paesmans M, Lecomte J, Van Cutsem O, Lafitte JJ, Berghmans T, et al. A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics. Br J Cancer 2001 Nov 16;85(10):1444-51.

   (112)    Chak LY, Daniels JR, Sikic BI, Torti FM, Lockbaum P, Carter SK. Patterns of failure in small cell carcinoma of the lung. Cancer 1982 Nov 1;50(9):1857-63.

   (113)                Osterlind K, Sorenson S, Hansen HH, Dombernowsky P, Hirsch FR, Hansen M, et al. Continuous versus alternating combination chemotherapy for advanced small cell carcinoma of the lung. Cancer Res 1983 Dec;43(12 Pt 1):6085-9.

   (114)    Daniels JR, Chak LY, Sikic BI, Lockbaum P, Kohler M, Carter SK, et al. Chemotherapy of small-cell carcinoma of lung: a randomized comparison of alternating and sequential combination chemotherapy programs. J Clin Oncol 1984 Nov;2(11):1192-9.

   (115)                Livingston RB, Mira JG, Chen TT, McGavran M, Costanzi JJ, Samson M. Combined modality treatment of extensive small cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1984 Jun;2(6):585-90.

   (116)    Maurer LH, Pajak T, Eaton W, Comis R, Chahinian P, Faulkner C, et al. Combined modality therapy with radiotherapy, chemotherapy, and immunotherapy in limited small-cell carcinoma of the lung: a Phase III cancer and Leukemia Group B Study. J Clin Oncol 1985 Jul;3(7):969-76.

   (117)    Feld R, Evans WK, Coy P, Hodson I, MacDonald AS, Osoba D, et al. Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. J Clin Oncol 1987 Sep;5(9):1401-9.

   (118)                Chahinian AP, Propert KJ, Ware JH, Zimmer B, Perry MC, Hirsh V, et al. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B [see comments]. J Clin Oncol 1989 Aug;7(8):993-1002.

   (119)                Havemann K, Wolf M, Drings P, Hans K, Schroeder M, Holle R, et al. Experience of a German multicenter study group with ifosfamide in small cell lung cancer. Semin Oncol 1989 Feb;16(1 Suppl 3):9-18.

   (120)                Goodman GE, Crowley JJ, Blasko JC, Livingston RB, Beck TM, Demattia MD, et al. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study. J Clin Oncol 1990 Jan;8(1):39-47.

   (121)    Wolf M, Pritsch M, Drings P, Hans K, Schroeder M, Flechtner H, et al. Cyclic-alternating versus response-oriented chemotherapy in small-cell lung cancer: a German multicenter randomized trial of 321 patients [see comments]. J Clin Oncol 1991 Apr;9(4):614-24.

   (122)    Wampler GL, Heim WJ, Ellison NM, Ahlgren JD, Fryer JG. Comparison of cyclophosphamide, doxorubicin, and vincristine with an alternating regimen of methotrexate, etoposide, and cisplatin/cyclophosphamide, doxorubicin, and vincristine in the treatment of extensive-disease small-cell lung carcinoma: a Mid- Atlantic Oncology Program study. J Clin Oncol 1991 Aug;9(8):1438-45.

   (123)    Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992 Feb;10(2):282-91.

   (124)    Joss RA, Alberto P, Bleher EA, Ludwig C, Siegenthaler P, Martinelli G, et al. Combined-modality treatment of small-cell lung cancer: randomized comparison of three induction chemotherapies followed by maintenance chemotherapy with or without radiotherapy to the chest. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 1994 Dec;5(10):921-8.

   (125)    Joss RA, Bacchi M, Hurny C, Bernhard J, Cerny T, Martinelli G, et al. Early versus late alternating chemotherapy in small-cell lung cancer. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 1995 Feb;6(2):157-66.

   (126)    Postmus PE, Scagliotti G, Groen HJ, Gozzelino F, Burghouts JT, Curran D, et al. Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC Phase III trial. Eur J Cancer 1996 Aug;32A(9):1498-503.

   (127)    Jett JR, Maksymiuk AW, Su JQ, Mailliard JA, Krook JE, Tschetter LK, et al. Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. J Clin Oncol 1994 Nov;12(11):2321-6.

   (128)    Kelly K, Crowley JJ, Bunn PAJ, Hazuka MB, Beasley K, Upchurch C, et al. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study. J Clin Oncol 1995 Dec;13(12):2924-30.

   (129)                Zarogoulidis K, Ziogas E, Papagiannis A, Charitopoulos K, Dimitriadis K, Economides D, et al. Interferon alpha-2a and combined chemotherapy as first line treatment in SCLC patients: a randomized trial. Lung Cancer 1996 Sep;15(2):197-205.

   (130)    van Zandwijk N, Groen HJ, Postmus PE, Burghouts JT, ten Velde GP, Ardizzoni A, et al. Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group [see comments]. Eur J Cancer 1997 Oct;33(11):1759-66.

   (131)    Prior C, Oroszy S, Oberaigner W, Schenk E, Kummer F, Aigner K, et al. Adjunctive interferon-alpha-2c in stage IIIB/IV small-cell lung cancer: a phase III trial [published erratum appears in Eur Respir J 1997 Apr;10(4):963]. Eur Respir J 1997 Feb;10(2):392-6.

   (132)                Ruotsalainen TM, Halme M, Tamminen K, Szopinski J, Niiranen A, Pyrhonen S, et al. Concomitant chemotherapy and IFN-alpha for small cell lung cancer: a randomized multicenter phase III study. J Interferon Cytokine Res 1999 Mar;19(3):253-9.

   (133)    Lebeau B, Chastang C, Muir JF, Vincent J, Massin F, Fabre C. No effect of an antiaggregant treatment with aspirin in small cell lung cancer treated with CCAVP16 chemotherapy. Results from a randomized clinical trial of 303 patients. The "Petites Cellules" Group. Cancer 1993 Mar 1;71(5):1741-5.

   (134)    Maurer LH, Herndon JE, Hollis DR, Aisner J, Carey RW, Skarin AT, et al. Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study. J Clin Oncol 1997 Nov;15(11):3378-87.